Should I buy or sell Zoetis stock right now?

7 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Zoetis in the last year. There are currently 7 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" ZTS shares. View ZTS analyst ratings or view top-rated stocks .

What is Zoetis' stock price target for 2024?

7 Wall Street research analysts have issued 1 year price objectives for Zoetis' stock. Their ZTS share price targets range from $195.00 to $260.00. On average, they predict the company's share price to reach $224.88 in the next year. This suggests a possible upside of 50.1% from the stock's current price. View analysts price targets for ZTS or view top-rated stocks among Wall Street analysts .

How have ZTS shares performed in 2024?

Zoetis' stock was trading at $197.37 at the beginning of 2024. Since then, ZTS shares have decreased by 24.1% and is now trading at $149.81. View the best growth stocks for 2024 here .

When is Zoetis' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, May 2nd 2024. View our ZTS earnings forecast .

How can I listen to Zoetis' earnings call?

Zoetis will be holding an earnings conference call on Thursday, May 2nd at 8:30 AM Eastern. Interested parties can register for or listen to the call using this link .

How were Zoetis' earnings last quarter?

Zoetis Inc. (NYSE:ZTS) released its quarterly earnings data on Tuesday, February, 13th. The company reported $1.24 EPS for the quarter, missing the consensus estimate of $1.32 by $0.08. The company had revenue of $2.21 billion for the quarter, compared to analyst estimates of $2.19 billion. Zoetis had a trailing twelve-month return on equity of 51.25% and a net margin of 27.43%. Zoetis's quarterly revenue was up 8.5% compared to the same quarter last year. During the same period last year, the business earned $1.15 earnings per share. Read the conference call transcript .

How often does Zoetis pay dividends? What is the dividend yield for Zoetis?

Zoetis announced a quarterly dividend on Tuesday, February 6th. Shareholders of record on Friday, April 19th will be given a dividend of $0.432 per share on Tuesday, June 4th. This represents a $1.73 annualized dividend and a dividend yield of 1.15%. The ex-dividend date is Thursday, April 18th. Read our dividend analysis for ZTS .

Is Zoetis a good dividend stock?

Zoetis (NYSE:ZTS) pays an annual dividend of $1.72 per share and currently has a dividend yield of 1.15%. The company has been increasing its dividend for 12 consecutive years, indicating the company has a strong committment to maintain and grow its dividend. The dividend payout ratio is 33.93%. This payout ratio is at a healthy, sustainable level, below 75%. Based on earnings estimates, ZTS will have a dividend payout ratio of 26.75% next year. This indicates that the company will be able to sustain or increase its dividend. Read our dividend analysis for ZTS .

What ETFs hold Zoetis' stock?

ETFs with the largest weight of Zoetis (NYSE:ZTS) stock in their portfolio include ProShares Pet Care ETF (PAWZ) , VanEck Agribusiness ETF (MOO) , iShares U.S. Pharmaceuticals ETF (IHE) , VanEck Pharmaceutical ETF (PPH) , SPDR S&P Pharmaceuticals ETF (XPH) , First Trust Nasdaq Pharmaceuticals ETF (FTXH) , Natixis Vaughan Nelson Select ETF (VNSE) and Direxion Daily Pharmaceutical & Medical Bull 3X Shares (PILL) .

What guidance has Zoetis issued on next quarter's earnings?

Zoetis updated its FY 2024 earnings guidance on Tuesday, February, 13th. The company provided earnings per share guidance of 5.740-5.840 for the period, compared to the consensus EPS estimate of 5.980. The company issued revenue guidance of $9.1 billion-$9.2 billion, compared to the consensus revenue estimate of $9.2 billion.

What is Kristin Peck's approval rating as Zoetis' CEO?

50 employees have rated Zoetis Chief Executive Officer Kristin Peck on Glassdoor.com . Kristin Peck has an approval rating of 82% among the company's employees. 70.0% of employees surveyed would recommend working at Zoetis to a friend.

What other stocks do shareholders of Zoetis own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Zoetis investors own include Xtrackers California Municipal Bond ETF (CA) , Endologix (ELGX) , BlackRock (BLK) , Chipotle Mexican Grill (CMG) , Hawkins (HWKN) , Aegean Marine Petroleum Network (ANW) , Athabasca Oil (ATH) , Micron Technology (MU) , Accenture (ACN) and Transocean (RIG) .

Who are Zoetis' major shareholders?

Zoetis' stock is owned by many different retail and institutional investors. Top institutional shareholders include Congress Asset Management Co. MA (0.15%), Los Angeles Capital Management LLC (0.08%), Sarasin & Partners LLP (0.08%), Wealth Enhancement Advisory Services LLC (0.05%), Neville Rodie & Shaw Inc. (0.03%) and Franklin Street Advisors Inc. NC (0.03%). Insiders that own company stock include Glenn David , Gregory Norden , Heidi C Chen , Kristin C Peck , Robert J Polzer , Roman Trawicki , Roxanne Lagano and Willie M Reed . View institutional ownership trends .

How do I buy shares of Zoetis?

Shares of ZTS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here .

Does Zoetis have any subsidiaries?

The following companies are subsidiares of Zoetis: Abaxis, Abaxis Asia Limited, Abaxis Europe GmbH, Abaxis Inc., Abaxis South East Europe d. o.o., Abaxis UK Limited, Alpharma Animal Health Company, Alpharma Animal Health Hong Kong Co. Limited, Alpharma Bermuda LLC, Alpharma Euro Holdings LLC, Alpharma Holdings Barbados SRL, Alpharma LLC, Alpharma Luxembourg S.A.R.L. y Compania Limitada, Alpharma do Brasil Ltda., Bovigen, Catapult Genetics Pty Ltd, Continental Farmaceutica SPRL, Cross Vetpharm Group Limited, Embrex LLC, Ethos Diagnostic Science, Fish Vet Group, Fish Vet Group Limited, Jilin Zoetis Guoyuan Animal Health Co. Ltd., Jorox Pty, King Animal Health, Microtek International Inc, Mikjan Corporation, Nexvet, Nexvet Australia Pty Ltd, PAH 7V6 Holding Limited, PAH CHHK Holding B.V., PAH India Holdco LLC, PAH India Holding 1 B.V., PAH Netherlands 2 B.V., PAH Oceania B.V., PAH Spain S.L., PHARMAQ, PT Zoetis Animalhealth Indonesia, Performance Livestock Analytics, Performance Livestock Analytics Inc., Pharmaq AS Chile Limitada, Pharmaq AS Service SpA, Pharmaq AS., Pharmaq Analytiq AS, Pharmaq Analytiq Limited, Pharmaq Analytiq SpA, Pharmaq Fishteq AS, Pharmaq Fishteq SpA, Pharmaq Ltd, Pharmaq Spain Aqua SL, Pharmaq Veterinar Ecza Deposu ve su Urunleri Ticaret Ltd Ski, Pharmaq Vietnam Company Limited, Phoenix Central Laboratory for Veterinarians Inc., Phoenix Lab, Platinum Performance, Platinum Performance Inc., Pumpkin Holdings Inc., Pumpkin Insurance Services Inc., Scandinavian Micro Biodevices, Smartbow GmbH, Smartbow RUS OOO, Synbiotics Corporation, Synbiotics LLC, Vetnex Animal Health Ltd, Virtual Recall, Virtual Recall Limited, Virtual Recall Pty Ltd, ZNLabs, ZNLabs LLC, ZOETISECUADOR Cia. Ltda., Zoetis Animal Health ApS, Zoetis Argentina S.R.L., Zoetis Australia Pty Ltd, Zoetis Australia Research & Manufacturing Pty Ltd, Zoetis B.V., Zoetis Belgium S.A., Zoetis Biopharmaceutical Co. Ltd, Zoetis Broomhill IP Limited, Zoetis Broomhill Property Limited, Zoetis C.A., Zoetis Canada Inc., Zoetis Colombia S.A.S., Zoetis Costa Rica S.R.L., Zoetis Denmark ApS, Zoetis Deutschland GmbH, Zoetis Egypt LLC, Zoetis Egypt Pharmaceuticals LLC, Zoetis Egypt Trading LLC, Zoetis Enterprise Management Shanghai Co. Ltd., Zoetis Finland Oy, Zoetis France, Zoetis Hayvan Sagligi Ltd. Sti., Zoetis Hellas S.A., Zoetis Holdings LLC, Zoetis Hungary Kft., Zoetis Import Egypt LLC, Zoetis India Limited, Zoetis Indústria de Produtos Veterinários Ltda., Zoetis International Holdings B.V., Zoetis Israël Holding B.V., Zoetis Italia S.r.l., Zoetis Japan K.K., Zoetis Korea Ltd., Zoetis LLC, Zoetis Luxembourg Holding S.à r.l., Zoetis Malaysia Sdn. Bhd., Zoetis Manufacturing & Research Spain S.L., Zoetis Manufacturing Italia S.R.L., Zoetis Medolla Manufacturing S.R.L., Zoetis Mexico S. de R.L. de C.V., Zoetis Netherlands 1 B.V., Zoetis Netherlands 3 B.V., Zoetis Netherlands 4 B.V., Zoetis Netherlands 5 B.V., Zoetis New Zealand Limited, Zoetis OOO, Zoetis Overseas Holding B.V., Zoetis Overseas Services Inc., Zoetis Panama S. de R.L., Zoetis Pharmaceutical Research Private Limited, Zoetis Philippines Inc., Zoetis Polska sp. z o.o, Zoetis Portugal Lda., Zoetis Products Inc., Zoetis Reference Laboratories China Co. Ltd., Zoetis Reference Labs LLC, Zoetis Romania SRL, Zoetis S.R.L., Zoetis Salud Animal de Bolivia S.A., Zoetis Schweiz GmbH, Zoetis Services LLC, Zoetis Singapore Pte. Ltd., Zoetis South Africa Pty Ltd., Zoetis Spain S.L., Zoetis Subsidiary Holdings Inc., Zoetis Suzhou Manufacturing Co. Ltd., Zoetis Sweden AB, Zoetis Taiwan Limited, Zoetis Thailand Limited, Zoetis Treasury Center BV, Zoetis UK Limited, Zoetis US LLC, Zoetis Ukraine LLC, Zoetis Vietnam Limited Liability Company, Zoetis WLC LLC, Zoetis Weesp B.V., Zoetis Yantai Manufacturing Co. Ltd., Zoetis de Chile S.A., Zoetis de Uruguay S.R.L., Zoetis Österreich GmbH, and Zoetis Česká republika s.r.o.. Read More

NYSE:ZTS

Zoetis (ZTS) Stock Price, News & Analysis

→ REVEALED: Elon Musk’s Secret A.I. Facility? (From InvestorPlace) (Ad)

Free ZTS Stock Alerts

$149.81

-0.17 (-0.11%)

(As of 04/15/2024 ET)

Compare

Today's Range: $149.24
▼
$154.93
50-Day Range: $149.81
▼
$199.94
52-Week Range: $148.48
▼
$201.92

Volume: 8.67 million shs
Average Volume: 3.42 million shs
Market Capitalization: $68.52 billion

P/E Ratio: 29.55
Dividend Yield: 1.15%
Price Target: $224.88

Get Zoetis alerts:

Zoetis MarketRank™ Stock Analysis

Analyst Rating: Buy
3.00 Rating Score
Upside/Downside: 50.1% Upside
$224.88 Price Target
Short Interest: Healthy
0.80% of Float Sold Short
Dividend Strength: Strong
Based on Four Factors
Sustainability: -4.66
Upright™ Environmental Score
News Sentiment: 0.16
Based on 52 Articles This Week
Insider Trading: Selling Shares
$408,453 Sold Last Quarter
Proj. Earnings Growth: 10.86%
From $5.80 to $6.43 Per Share

Overall MarketRank^™

New Rank-Based ScoringMarketRank^™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

4.80 out of 5 stars

Medical Sector

42nd out of 928 stocks

Pharmaceutical Preparations Industry

16th out of 434 stocks

3.5

Analyst's Opinion

Consensus Rating
Zoetis has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 7 buy ratings, no hold ratings, and no sell ratings.
Amount of Analyst Coverage
Zoetis has only been the subject of 4 research reports in the past 90 days.

3.0

Short Interest

Percentage of Shares Shorted
0.80% of the float of Zoetis has been sold short.
Short Interest Ratio / Days to Cover
Zoetis has a short interest ratio ("days to cover") of 1.3, which is generally considered an acceptable ratio of short interest to trading volume.
Change versus previous month
Short interest in Zoetis has recently increased by 2.24%, indicating that investor sentiment is decreasing.

4.2

Dividend Strength

Dividend Yield
Zoetis pays a meaningful dividend of 1.15%, higher than the bottom 25% of all stocks that pay dividends.
Dividend Growth
Zoetis has been increasing its dividend for 12 years.
Dividend Coverage
The dividend payout ratio of Zoetis is 33.93%. This payout ratio is at a healthy, sustainable level, below 75%.
Dividend Sustainability
Based on earnings estimates, Zoetis will have a dividend payout ratio of 26.75% next year. This indicates that Zoetis will be able to sustain or increase its dividend.

0.4

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
Zoetis has received a -79.93% net impact score from Upright. The largest negative impact of Zoetis in category "GHG emissions" seems to be driven mostly by its "Cattle antibiotics", "Cattle vaccines", "Vaccines for pet animals", "Antibiotics for pet animals", and "Cattle dewormers" products. See details.
Environmental Sustainability
The Environmental Impact score for Zoetis is -4.66.

2.9

News and Social Media Coverage

News Sentiment
Zoetis has a news sentiment score of 0.16. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.66 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 52 news articles for Zoetis this week, compared to 10 articles on an average week.
Search Interest
93 people have searched for ZTS on MarketBeat in the last 30 days. This is an increase of 66% compared to the previous 30 days.
MarketBeat Follows
100 people have added Zoetis to their MarketBeat watchlist in the last 30 days. This is an increase of 72% compared to the previous 30 days.

2.5

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Zoetis insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $408,453.00 in company stock.
Percentage Held by Insiders
Only 0.12% of the stock of Zoetis is held by insiders.
Percentage Held by Institutions
92.80% of the stock of Zoetis is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

2.5

Earnings and Valuation

Earnings Growth
Earnings for Zoetis are expected to grow by 10.86% in the coming year, from $5.80 to $6.43 per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Zoetis is 29.55, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 132.07.
Price to Earnings Ratio vs. Sector
The P/E ratio of Zoetis is 29.55, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 166.67.
Price to Earnings Growth Ratio
Zoetis has a PEG Ratio of 2.29. PEG Ratios above 1 indicate that a company could be overvalued.
Price to Book Value per Share Ratio
Zoetis has a P/B Ratio of 13.78. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

Ad InvestorPlace

Elon Musk’s ChatGPT Could Soon Mint New Millionaires

Elon Musk made $180 million on PayPal… $47 Billion on SpaceX…and $94.2 Billion on Tesla. He’s about to shock the world again with his version of ChatGPT.

And you could go along for the ride if you make this one simple move.

About Zoetis Stock (NYSE:ZTS)

Zoetis Inc. engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses. It also offers parasiticides, vaccines, dermatology, other pharmaceutical, anti-infectives, animal health diagnostics, and medicated feed additives. In addition, the company provides animal health diagnostics, including point-of-care diagnostic products, instruments and reagents, rapid immunoassay tests, reference laboratory kits and services, and blood glucose monitors; and other non-pharmaceutical products, which include nutritionals, as well as products and services in biodevices, genetic tests, and precision animal health. It markets its products to veterinarians, livestock producers, and pet owners. The company has collaboration Blacksmith Medicines, Inc. to discover and develop novel antibiotics for animal health. Zoetis Inc. was founded in 1952 and is headquartered in Parsippany, New Jersey.

ZTS Stock Price History

30 days | 90 days | 365 days | Advanced Chart

ZTS Stock News Headlines

March 19, 2024 | insidertrades.com

Insider Selling: Zoetis Inc. (NYSE:ZTS) EVP Sells 923 Shares of Stock

April 15, 2024 | businesswire.com

ZTS LOSS ALERT: ROSEN, TOP RANKED INVESTOR COUNSEL, Encourages Zoetis Inc. Investors to Inquire About Securities Class Action Investigation – ZTS

April 16, 2024 | InvestorPlace (Ad)

Elon Musk’s ChatGPT Could Soon Mint New Millionaires

Elon Musk made $180 million on PayPal… $47 Billion on SpaceX…and $94.2 Billion on Tesla. He’s about to shock the world again with his version of ChatGPT.

April 15, 2024 | finance.yahoo.com

Zoetis (ZTS) Stock Moves -0.14%: What You Should Know

April 15, 2024 | stockhouse.com

ZTS LOSS ALERT: ROSEN, TOP RANKED INVESTOR COUNSEL, Encourages Zoetis Inc. Investors to Inquire About Securities Class Action Investigation - ZTS

April 15, 2024 | businesswire.com

ZTS Investigation Alert: Kessler Topaz Meltzer & Check, LLP Encourages Zoetis Inc. (NYSE: ZTS) Investors with Losses to Contact the Firm

April 14, 2024 | seekingalpha.com

Despite Lawsuit Risks: Why Zoetis Remains A Compelling Investment

April 14, 2024 | morningstar.com

Zoetis's stock falls 8% after report that its arthritis shots may have sickened pets

April 16, 2024 | InvestorPlace (Ad)

Elon Musk’s ChatGPT Could Soon Mint New Millionaires

Elon Musk made $180 million on PayPal… $47 Billion on SpaceX…and $94.2 Billion on Tesla. He’s about to shock the world again with his version of ChatGPT.

April 14, 2024 | americanbankingnews.com

Zoetis (NYSE:ZTS) Shares Down 7.8%

April 14, 2024 | americanbankingnews.com

Zoetis (NYSE:ZTS) Hits New 52-Week Low at $148.71

April 14, 2024 | americanbankingnews.com

Zoetis Inc. (NYSE:ZTS) Given Consensus Recommendation of "Buy" by Analysts

April 13, 2024 | msn.com

Zoetis hits 52-week low on adverse events linked to arthritis drugs (update)

April 13, 2024 | msn.com

Zoetis’s stock falls 8% after report that its arthritis shots may have sickened pets

April 12, 2024 | bloomberg.com

Zoetis Sinks Most in 17 Months After Report on Pet Arthritis Drugs

April 12, 2024 | msn.com

Zoetis Stock Slumps on Report Suggesting Its Arthritis Drugs May Make Pets Sick

April 12, 2024 | nasdaq.com

Zoetis Becomes Oversold

April 12, 2024 | za.investing.com

Zoetis stock drops following WSJ report on pet arthritis drugs

April 12, 2024 | msn.com

Top Stock Movers Now: JPMorgan, Intel, Zoetis, and More

April 12, 2024 | benzinga.com

A Closer Look at Zoetis's Options Market Dynamics

April 12, 2024 | msn.com

Zoetis slips on reports of adverse effects linked to arthritis drugs

April 12, 2024 | msn.com

Animal Health Giant Zoetis Stock Crumbles: Possible Side Effect Of Its Pet Arthritis Pain Drugs Sickened Dogs, Cats

April 12, 2024 | finance.yahoo.com

Zoetis Stock Falls After Journal Reports Scrutiny of Its Arthritis Drugs for Pets

April 12, 2024 | finance.yahoo.com

Zoetis Stock Falls on Concerns Over Pet Arthritis Drugs. Company Says They’re Safe.

April 12, 2024 | finance.yahoo.com

Zoetis Stock Crumbles After Report Suggests Arthritis Shots Sickened Dogs, Cats

April 12, 2024 | proactiveinvestors.com

Zoetis shares drop amid concerns over arthritis shots' safety for pets

April 12, 2024 | barrons.com

Zoetis Stock Falls on Concerns Over Pet Arthritis Drugs. Company Says They're Safe.

See More Headlines

Receive ZTS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Zoetis and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Ex-Dividend for 3/1 Dividend: 1/18/2024
Last Earnings: 2/13/2024
Dividend Payable: 3/01/2024
Today: 4/16/2024
Ex-Dividend for 6/4 Dividend: 4/18/2024
Next Earnings (Confirmed): 5/02/2024
Dividend Payable: 6/04/2024
Fiscal Year End: 12/31/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NYSE
Sector: Medical
Industry: Pharmaceutical preparations
Sub-Industry: Pharmaceuticals
Current Symbol: NYSE:ZTS
CUSIP: 98978V10
CIK: 1555280
Web: www.zoetis.com
Phone: (973) 822-7000
Fax: 302-655-5049
Employees: 14,100
Year Founded: 2012

Price Target and Rating

Average Stock Price Target: $224.88
High Stock Price Target: $260.00
Low Stock Price Target: $195.00
Potential Upside/Downside: +50.1%
Consensus Rating: Buy
Rating Score (0-4): 3.00
Research Coverage: 7 Analysts

Profitability

EPS (Most Recent Fiscal Year): $5.07
Trailing P/E Ratio: 29.55
Forward P/E Ratio: 25.83
P/E Growth: 2.29
Net Income: $2.34 billion
Net Margins: 27.43%
Pretax Margin: 34.36%
Return on Equity: 51.25%
Return on Assets: 17.58%

Debt

Debt-to-Equity Ratio: 1.32
Current Ratio: 3.36
Quick Ratio: 2.00

Sales & Book Value

Annual Sales: $8.54 billion
Price / Sales: 8.02
Cash Flow: $6.41 per share
Price / Cash Flow: 23.36
Book Value: $10.87 per share
Price / Book: 13.78

Miscellaneous

Outstanding Shares: 457,360,000
Free Float: 456,673,000
Market Cap: $68.52 billion
Optionable: Optionable
Beta: 0.85

Social Links

7 Energy Stocks to Buy and Hold Forever

Do you expect the global demand for energy to shrink?! If not, it's time to take a look at how energy stocks can play a part in your portfolio.

Get This Free Report

Key Executives

Ms. Kristin C. Peck (Age 53)
CEO & Director
Comp: $2.8M
Mr. Wetteny N. Joseph (Age 52)
Executive VP & CFO
Comp: $1.26M
Ms. Wafaa Mamilli (Age 57)
EVP, Chief Digital & Tech. Officer, Group President for China, Brazil and Preci. Animal Health
Comp: $1.08M
Ms. Heidi C. Chen (Age 57)
Executive VP, General Counsel, Corporate Secretary & Business Lead of Human Health Diagnostics
Comp: $1.04M
Ms. Roxanne Lagano (Age 59)
Executive VP and Chief Human Resources Officer & Global Operations
Mr. Steven Frank
Vice President of Investor Relations
Mr. William Price
VP & Chief Communications Officer
Dr. Robert J. Polzer Ph.D. (Age 55)
Executive VP and President of Research & Development
Ms. Jeannette Ferran Astorga (Age 49)
Executive VP of Corporate Affairs & Communications and Chief Sustainability Officer
Mr. Nick Ashton (Age 51)
Executive VP and President of Global Manufacturing & Supply

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

Should I Buy Zoetis Stock? ZTS Pros and Cons Explained

Pros

Here are some ways that investors could benefit from investing in Zoetis Inc.:

Zoetis Inc. engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products, catering to a wide range of animals from livestock to companion animals. This diversified product portfolio can provide stability and growth opportunities.
The company collaborates with Blacksmith Medicines, Inc. to discover and develop novel antibiotics for animal health, showcasing a commitment to innovation and addressing emerging needs in the industry.
Zoetis Inc. offers a variety of products and services in biodevices, genetic tests, and precision animal health, indicating a focus on cutting-edge technologies that could drive future revenue growth.
With a strong market presence and a history dating back to 1952, Zoetis Inc. has established itself as a reputable player in the animal health industry, instilling confidence in investors.
Considering the current stock price and recent performance trends, Zoetis Inc. shows potential for capital appreciation, making it an attractive investment option for growth-oriented investors.

Cons

Investors should be bearish about investing in Zoetis Inc. for these reasons:

While Zoetis Inc. operates in the pharmaceutical preparations industry, which can be lucrative, it also faces regulatory challenges and competition that may impact its market position and profitability.
The animal health industry is subject to economic cycles and external factors, such as disease outbreaks or changes in consumer preferences, which could affect Zoetis Inc.'s financial performance and stock value.
Investing in Zoetis Inc. involves exposure to risks associated with research and development of new products, including uncertainties in product efficacy, regulatory approvals, and market acceptance, which could lead to financial setbacks.
As a publicly traded company, Zoetis Inc. is susceptible to market volatility and investor sentiment, which may result in fluctuations in its stock price and potential losses for shareholders.
Investors should carefully assess their risk tolerance and investment objectives before considering Zoetis Inc. as an investment, as the company's performance may not always align with market expectations or macroeconomic conditions.

These pros and cons were generated based on recent news and financial data from MarketBeat in order to provide readers with the fastest and most accurate insights. They were last updated on Saturday, April 13, 2024. Please send any questions or comments about these Zoetis pros and cons to contact@marketbeat.com.

ZTS Stock Analysis - Frequently Asked Questions

Should I buy or sell Zoetis stock right now?: 7 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Zoetis in the last year. There are currently 7 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" ZTS shares.
View ZTS analyst ratings or view top-rated stocks.
What is Zoetis' stock price target for 2024?: 7 Wall Street research analysts have issued 1 year price objectives for Zoetis' stock. Their ZTS share price targets range from $195.00 to $260.00. On average, they predict the company's share price to reach $224.88 in the next year. This suggests a possible upside of 50.1% from the stock's current price.
View analysts price targets for ZTS or view top-rated stocks among Wall Street analysts.
How have ZTS shares performed in 2024?: Zoetis' stock was trading at $197.37 at the beginning of 2024. Since then, ZTS shares have decreased by 24.1% and is now trading at $149.81.
View the best growth stocks for 2024 here.
When is Zoetis' next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Thursday, May 2nd 2024.
View our ZTS earnings forecast.
How can I listen to Zoetis' earnings call?: Zoetis will be holding an earnings conference call on Thursday, May 2nd at 8:30 AM Eastern. Interested parties can register for or listen to the call using this link.
How were Zoetis' earnings last quarter?: Zoetis Inc. (NYSE:ZTS) released its quarterly earnings data on Tuesday, February, 13th. The company reported $1.24 EPS for the quarter, missing the consensus estimate of $1.32 by $0.08. The company had revenue of $2.21 billion for the quarter, compared to analyst estimates of $2.19 billion. Zoetis had a trailing twelve-month return on equity of 51.25% and a net margin of 27.43%. Zoetis's quarterly revenue was up 8.5% compared to the same quarter last year. During the same period last year, the business earned $1.15 earnings per share.
Read the conference call transcript.
How often does Zoetis pay dividends? What is the dividend yield for Zoetis?: Zoetis announced a quarterly dividend on Tuesday, February 6th. Shareholders of record on Friday, April 19th will be given a dividend of $0.432 per share on Tuesday, June 4th. This represents a $1.73 annualized dividend and a dividend yield of 1.15%. The ex-dividend date is Thursday, April 18th.
Read our dividend analysis for ZTS.
Is Zoetis a good dividend stock?: Zoetis (NYSE:ZTS) pays an annual dividend of $1.72 per share and currently has a dividend yield of 1.15%. The company has been increasing its dividend for 12 consecutive years, indicating the company has a strong committment to maintain and grow its dividend. The dividend payout ratio is 33.93%. This payout ratio is at a healthy, sustainable level, below 75%. Based on earnings estimates, ZTS will have a dividend payout ratio of 26.75% next year. This indicates that the company will be able to sustain or increase its dividend.
Read our dividend analysis for ZTS.

What ETFs hold Zoetis' stock?: ETFs with the largest weight of Zoetis (NYSE:ZTS) stock in their portfolio include ProShares Pet Care ETF (PAWZ), VanEck Agribusiness ETF (MOO), iShares U.S. Pharmaceuticals ETF (IHE), VanEck Pharmaceutical ETF (PPH), SPDR S&P Pharmaceuticals ETF (XPH), First Trust Nasdaq Pharmaceuticals ETF (FTXH), Natixis Vaughan Nelson Select ETF (VNSE) and Direxion Daily Pharmaceutical & Medical Bull 3X Shares (PILL).
What guidance has Zoetis issued on next quarter's earnings?: Zoetis updated its FY 2024 earnings guidance on Tuesday, February, 13th. The company provided earnings per share guidance of 5.740-5.840 for the period, compared to the consensus EPS estimate of 5.980. The company issued revenue guidance of $9.1 billion-$9.2 billion, compared to the consensus revenue estimate of $9.2 billion.
What is Kristin Peck's approval rating as Zoetis' CEO?: 50 employees have rated Zoetis Chief Executive Officer Kristin Peck on Glassdoor.com. Kristin Peck has an approval rating of 82% among the company's employees. 70.0% of employees surveyed would recommend working at Zoetis to a friend.
What other stocks do shareholders of Zoetis own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Zoetis investors own include Xtrackers California Municipal Bond ETF (CA), Endologix (ELGX), BlackRock (BLK), Chipotle Mexican Grill (CMG), Hawkins (HWKN), Aegean Marine Petroleum Network (ANW), Athabasca Oil (ATH), Micron Technology (MU), Accenture (ACN) and Transocean (RIG).
Who are Zoetis' major shareholders?: Zoetis' stock is owned by many different retail and institutional investors. Top institutional shareholders include Congress Asset Management Co. MA (0.15%), Los Angeles Capital Management LLC (0.08%), Sarasin & Partners LLP (0.08%), Wealth Enhancement Advisory Services LLC (0.05%), Neville Rodie & Shaw Inc. (0.03%) and Franklin Street Advisors Inc. NC (0.03%). Insiders that own company stock include Glenn David, Gregory Norden, Heidi C Chen, Kristin C Peck, Robert J Polzer, Roman Trawicki, Roxanne Lagano and Willie M Reed.
View institutional ownership trends.
How do I buy shares of Zoetis?: Shares of ZTS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.
Does Zoetis have any subsidiaries?: The following companies are subsidiares of Zoetis: Abaxis, Abaxis Asia Limited, Abaxis Europe GmbH, Abaxis Inc., Abaxis South East Europe d. o.o., Abaxis UK Limited, Alpharma Animal Health Company, Alpharma Animal Health Hong Kong Co. Limited, Alpharma Bermuda LLC, Alpharma Euro Holdings LLC, Alpharma Holdings Barbados SRL, Alpharma LLC, Alpharma Luxembourg S.A.R.L. y Compania Limitada, Alpharma do Brasil Ltda., Bovigen, Catapult Genetics Pty Ltd, Continental Farmaceutica SPRL, Cross Vetpharm Group Limited, Embrex LLC, Ethos Diagnostic Science, Fish Vet Group, Fish Vet Group Limited, Jilin Zoetis Guoyuan Animal Health Co. Ltd., Jorox Pty, King Animal Health, Microtek International Inc, Mikjan Corporation, Nexvet, Nexvet Australia Pty Ltd, PAH 7V6 Holding Limited, PAH CHHK Holding B.V., PAH India Holdco LLC, PAH India Holding 1 B.V., PAH Netherlands 2 B.V., PAH Oceania B.V., PAH Spain S.L., PHARMAQ, PT Zoetis Animalhealth Indonesia, Performance Livestock Analytics, Performance Livestock Analytics Inc., Pharmaq AS Chile Limitada, Pharmaq AS Service SpA, Pharmaq AS., Pharmaq Analytiq AS, Pharmaq Analytiq Limited, Pharmaq Analytiq SpA, Pharmaq Fishteq AS, Pharmaq Fishteq SpA, Pharmaq Ltd, Pharmaq Spain Aqua SL, Pharmaq Veterinar Ecza Deposu ve su Urunleri Ticaret Ltd Ski, Pharmaq Vietnam Company Limited, Phoenix Central Laboratory for Veterinarians Inc., Phoenix Lab, Platinum Performance, Platinum Performance Inc., Pumpkin Holdings Inc., Pumpkin Insurance Services Inc., Scandinavian Micro Biodevices, Smartbow GmbH, Smartbow RUS OOO, Synbiotics Corporation, Synbiotics LLC, Vetnex Animal Health Ltd, Virtual Recall, Virtual Recall Limited, Virtual Recall Pty Ltd, ZNLabs, ZNLabs LLC, ZOETISECUADOR Cia. Ltda., Zoetis Animal Health ApS, Zoetis Argentina S.R.L., Zoetis Australia Pty Ltd, Zoetis Australia Research & Manufacturing Pty Ltd, Zoetis B.V., Zoetis Belgium S.A., Zoetis Biopharmaceutical Co. Ltd, Zoetis Broomhill IP Limited, Zoetis Broomhill Property Limited, Zoetis C.A., Zoetis Canada Inc., Zoetis Colombia S.A.S., Zoetis Costa Rica S.R.L., Zoetis Denmark ApS, Zoetis Deutschland GmbH, Zoetis Egypt LLC, Zoetis Egypt Pharmaceuticals LLC, Zoetis Egypt Trading LLC, Zoetis Enterprise Management Shanghai Co. Ltd., Zoetis Finland Oy, Zoetis France, Zoetis Hayvan Sagligi Ltd. Sti., Zoetis Hellas S.A., Zoetis Holdings LLC, Zoetis Hungary Kft., Zoetis Import Egypt LLC, Zoetis India Limited, Zoetis Indústria de Produtos Veterinários Ltda., Zoetis International Holdings B.V., Zoetis Israël Holding B.V., Zoetis Italia S.r.l., Zoetis Japan K.K., Zoetis Korea Ltd., Zoetis LLC, Zoetis Luxembourg Holding S.à r.l., Zoetis Malaysia Sdn. Bhd., Zoetis Manufacturing & Research Spain S.L., Zoetis Manufacturing Italia S.R.L., Zoetis Medolla Manufacturing S.R.L., Zoetis Mexico S. de R.L. de C.V., Zoetis Netherlands 1 B.V., Zoetis Netherlands 3 B.V., Zoetis Netherlands 4 B.V., Zoetis Netherlands 5 B.V., Zoetis New Zealand Limited, Zoetis OOO, Zoetis Overseas Holding B.V., Zoetis Overseas Services Inc., Zoetis Panama S. de R.L., Zoetis Pharmaceutical Research Private Limited, Zoetis Philippines Inc., Zoetis Polska sp. z o.o, Zoetis Portugal Lda., Zoetis Products Inc., Zoetis Reference Laboratories China Co. Ltd., Zoetis Reference Labs LLC, Zoetis Romania SRL, Zoetis S.R.L., Zoetis Salud Animal de Bolivia S.A., Zoetis Schweiz GmbH, Zoetis Services LLC, Zoetis Singapore Pte. Ltd., Zoetis South Africa Pty Ltd., Zoetis Spain S.L., Zoetis Subsidiary Holdings Inc., Zoetis Suzhou Manufacturing Co. Ltd., Zoetis Sweden AB, Zoetis Taiwan Limited, Zoetis Thailand Limited, Zoetis Treasury Center BV, Zoetis UK Limited, Zoetis US LLC, Zoetis Ukraine LLC, Zoetis Vietnam Limited Liability Company, Zoetis WLC LLC, Zoetis Weesp B.V., Zoetis Yantai Manufacturing Co. Ltd., Zoetis de Chile S.A., Zoetis de Uruguay S.R.L., Zoetis Österreich GmbH, and Zoetis Česká republika s.r.o..
Read More

This page (NYSE:ZTS) was last updated on 4/16/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

Zoetis (ZTS) Stock Price, News & Analysis

Zoetis MarketRank™ Stock Analysis

Overall MarketRank™

Analyst's Opinion

Short Interest

Percentage of Shares Shorted

Short Interest Ratio / Days to Cover

Change versus previous month

Dividend Strength

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score

Environmental Sustainability

News and Social Media Coverage

News Sentiment

News Coverage This Week

Search Interest

MarketBeat Follows

Company Ownership

Earnings and Valuation

About Zoetis Stock (NYSE:ZTS)

ZTS Stock Price History

ZTS Stock News Headlines

Company Calendar

Industry, Sector and Symbol

Price Target and Rating

Profitability

Debt

Sales & Book Value

Miscellaneous

Social Links

Key Executives

Key Competitors

Insiders & Institutions

Should I Buy Zoetis Stock? ZTS Pros and Cons Explained

Pros

Cons

ZTS Stock Analysis - Frequently Asked Questions

Overall MarketRank^™